Although comprehensive obesity treatment programmes were shown to induce weight loss and to improve risk factors and comorbidities, the weight reduction is moderate and most patients will rapidly regain weight. For these reasons, drugs have been developed or are in development to support and maintain weight loss. At present, two drugs are available for the adjunct treatment of obesity. Sibutramine is a centrally acting inhibitor of noradrenaline and serotonine reuptake, thereby decreasing caloric intake and increasing energy expenditure. Orlistat is a specific lipase inhibitor that impairs fat absorption, thereby reducing fat uptake. Both drugs have been found to be effective and safe in a number of clinical studies for up to two years. The current experience with these drugs raises questions related to the long-term efficacy with particular reference to cardiovascular end-points. In addition, other current and future pharmacological principles for weight reduction are discussed. There is no doubt that an evidence-based rational pharmacological treatment of obesity is still in an early stage.
Introduction
The rising prevalence of obesity and obesity-associated diseases represents a tremendous challenge to clinicians and healthcare systems all over the world. In Europe, between 15 and 20% of the adult population have a BMI 30 kg=m 2 and are at high risk of developing a variety of serious complications which not only reduce the quality of life but may also reduce life expectancy. 1 In a recent analysis, the contribution of obesity-related conditions to mortality was estimated to be in the range of almost 300 000 deaths per year in the United States alone, ranking obesity second to smoking as a preventable cause of death. 2 Although a broad spectrum of dietary treatment options to lower excess body weight is available, there is agreement among experts that all these methods result in only a limited and short-term weight loss. 3 However, in many obese individuals a more marked and sustained weight reduction is desirable to reduce the considerable health risks. Even multidisciplinary approaches including dietary measures, increase in physical activity and behavior modification do not provide a satisfactory success rate, particularly if long-term results are considered.
Therefore the use of weight-lowering drugs has been proposed as a more effective treatment choice for obesity. However, the development of the first of such agents (eg amphetamines) was not only disappointing in terms of efficacy but turned out to cause a number of partially severe adverse effects which finally led to the withdrawal of most of these compounds. 4 The second era of drug treatment of obesity began almost a decade ago when dexfenfluramine was approved for adjunct treatment of obesity in Europe and a few years later in the US. However, after the widespread use of fenfluramine and its active dextrorotatory isomer dexfenfluramine, reports were published which showed that the use of these serotoninergic drugs alone or in combination with phentermine ('fen-phen') was associated with an elevated risk of primary pulmonary hypertension 5 and unusual forms of valvular heart disease 6 which resulted in the withdrawal of both fenfluramine and dexfenfluramine from the market in 1997.
Despite these severe drawbacks, the efforts to develop new drugs to support and maintain weight loss were intensified during recent years. In particular, the discovery of leptin drew growing attention to the complex pathophysiology of obesity. 7 In addition, alarming figures on the worldwide rise of overweight and obesity prompted governments to support obesity research 1 and to fund public health initiatives focussed on obesity. Today, obesity is recognized in many countries as a chronic disease of multifactorial origin which requires long-term if not lifelong management.
There is now a broad consensus among experts that drug treatment should only be considered if safe and effective drugs are available. There is also agreement that drugs should only be used if the BMI exceeds 30 kg=m 2 or if it exceeds at least 27 kg=m 2 and obesity-related comorbidities such as hypertension or type 2 diabetes are present. Only if conventional treatment consisting of a hypocaloric diet, increase in physical activity and behavior modification have proven to be uneffective (weight loss < 5% of initial body weight within 3 to 6 months of treatment) can drugs be considered and they should only be initiated if the assessment of possible benefits and risks is clearly in favour of treatment. It is extremely important to note that drugs should be used as an adjunct to a non-pharmacological treatment programme. 8 -12 Principles of action of weight lowering drugs
The pharmacological compounds which are currently in use or under investigation act either via central nervous pathways or via the gastrointestinal tract. Table 1 summarizes the main principles of action and model compounds which are currently discussed and studied. Recently, two new weightlowering drugs received approval by the health authorities in the US and in many European countries as well as in many other countries worldwide. These two drugs, sibutramine and orlistat, have been more carefully studied than any weight-lowering drug before.
Sibutramine
Sibutramine is a selective serotonine-and noradrenalinereuptake inhibitor, but also blocks dopamine reuptake to some extent. 13, 14 Via these central mechanisms of action sibutramine reduces food intake and increases energy expenditure. In a clinical study of 12 non-dieting obese women, sibutramine was found to decrease spontaneous energy intake by 19% after 14 days of 10 mg sibutramine administration and by 26% under 30 mg sibutramine for the same period as compared to placebo. In addition, there was a slight increase in the percentage of energy consumed from carbohydrates. 15 The available data on a possible thermogenic action of sibutramine are controversial. Hansen et al reported an increase in energy expenditure in the fasting state as well as after a meal which was associated with increases in plasma epinephrine, heart rate and blood pressure. 16 In a randomized, placebo-controlled study by Seagle et al there was no significant acute or long-term effect of sibutramine on the resting metabolic rate. 17 In two very recent studies sibutramine was found to significantly reduce the decline in energy expenditure that follows dietary weight loss. 18, 19 Short-term studies originally established that sibutramine produces a dose-dependent weight loss in obese subjects and is well tolerated. 20, 21 There are now data from one-year and longer trials that clearly show a significantly greater weight loss with 10 or 15 mg sibutramine once daily versus placebo treatment. 22 -24 The net effect of sibutramine in these studies was a weight loss in the range of 3 to 6 kg. In one of these studies sibutramine was examined in primary care medicine. It turned out that sibutramine was most effective in those patients who were less successful with the non-pharmacological treatment programme. 24 In another study, Apfelbaum et al evaluated the potential of sibutramine to maintain weight after a 4-week very-low-calorie diet where participants lost on average 7.4 and 7.7 kg, respectively. During the following 12 months the completers under 10 mg sibutramine reduced their body weight by an additional 5.2 kg, while the patients under placebo treatment had a small weight gain of 0.5 kg. 25 The most frequent adverse effects under sibutramine treatment are dry mouth, insomnia, anorexia and constipation with a prevalence between 10 and 20%.
14 Due to its noradrenergic action sibutramine also induces a small increase in heart rate of 3 -5 beats=minute. Sibutramine causes a transient increase in both systolic and diastolic blood pressure by a mean of 2 -4 mmHg at doses of 10 and 15 mg per day, respectively. However, the usually rapid and greater weight loss observed under sibutramine treatment leads to a net decrease in blood pressure. Due to these side effects, careful monitoring of patients is required after 
Orlistat
Orlistat is a specific inhibitor of gastric and pancreatic lipases which reduces gastrointestinal fat absorption by approximately 30%. It is the hydrogenated derivative of lipstatin produced by the bacterium Streptococcus toxytricini. 26 By reducing fat absorption, orlistat induces a negative energy balance and thus weight reduction which depends on the amount of fat intake and the dose of orlistat. 27 Results from several studies demonstrate the efficacy and safety of the use of this drug for up to 2 y. 28 In a multicenter European trial patients receiving 120 mg orlistat t.i.d. lost 3.9 kg more weight after 1 y than placebo-treated participants. During the second year, those who continued with orlistat regained on average half as much as those switched to placebo. 29 Similar results were published from two US trials conducted both in research centers and in primary care centers. The net effect of 120 mg orlistat t.i.d. was in the range 3 -4 kg. Again, orlistat was found to lessen weight regain in the second year of treatment. 30, 31 The main adverse effects of orlistat treatment affect the gastrointestinal tract and are due to its specific action. These adverse events include fecal urgency, oily spotting, fatty stool, flatus and discharge, increased defecation and fecal incontinence, occurring with a frequency of 10 to 30%. In approximately 5 to 15% of patients, a decrease in the serum concentrations of fat-soluble vitamins is observed. Most of these patients received supplementation with b-carotene, vitamin A or E. 29 -31 Pharmacokinetic analysis indicates a low systemic absorption of orlistat (less than 1%) without evidence of accumulation. 28, 29 Pharmacodynamic studies suggest that orlistat does not affect the absorption of other drugs. 28 
Type 2 diabetes
One important indication for weight-lowering agents is their application in overweight patients with type 2 diabetes mellitus. In a 12-week study, 15 mg sibutramine induced a greater weight loss than placebo (mean difference 2.4 kg, P < 0.001). Mean Hb A1 c levels decreased by 0.3% under sibutramine treatment and remained unchanged with placebo. 32 Similar results are available for orlistat. In a 12-month study, orlistat caused a greater weight loss than placebo treatment (mean difference 1.9 kg, P < 0.001). Orlistat treatment was also associated with a significant decrease in Hb A1 c and fasting blood glucose and a dosage reduction of oral sulfonylurea medication. 33 In a recent study, orlistat was also reported to significantly improve glucose tolerance and to diminish the rate of progression to the development of impaired glucose tolerance and type 2 diabetes mellitus. 34 
Hypertension
Elevated blood pressure is a frequent risk factor associated with obesity. In the orlistat trials, there was a small decrease in both systolic and diastolic blood pressure in proportion to weight loss. 29 -31 The situation is more complex under sibutramine treatment as this drug has a noradrenergic action and produces a small dose-related increase in blood pressure. 4, 22 Although blood pressure decreases with weight loss, this stimulatory effect on blood pressure remains detectable as long as sibutramine is taken. In a few patients, there may be an unexpected rise in blood pressure after administration of sibutramine which requires close monitoring at the beginning of treatment. However, most patients with stable hypertension will benefit from treatment. In one study, participants with a baseline blood pressure 140= 90 mmHg showed a significant decrease after one year of treatment with 15 mg sibutramine compared to baseline. 24 Nevertheless the fall in blood pressure is usually smaller than would be expected from the decrease in body weight. 21 
Dyslipidaemia
Weight loss is usually associated with an improvement in the lipid profile. 9 The additional weight loss produced by sibutramine and orlistat is accompanied by a graded decrease in total and LDL-cholesterol as well as an increase in HDLcholesterol. In all studies with orlistat there was a reduction in serum lipid levels. For example, after 2 y of treatment with orlistat, the magnitude of the effect was 11 mg=dl for total cholesterol and 8 mg=dl for LDL-cholesterol. No significant alteration was seen for HDL-cholesterol and triglycerides. 30 In the European multicenter trial, the authors even stated that total and LDL-cholesterol concentrations fell further than would be expected from weight loss alone. This independent cholesterol-lowering effect was explained by the ability of orlistat to specifically reduce fat uptake. 29 Analysis of the lipid data in the sibutramine trials indicate that sibutramine may have an independent beneficial effect on HDL-cholesterol (Lauterbach et al personal communication). These aspects require further detailed studies.
Other compounds with weight lowering potential
There are a number of other drugs approved for other diseases which have some potential for body weight control and which may be preferable under certain clinical conditions. The amylase inhibitor acarbose is used for the treatPharmacological approaches to treating obesity H Hauner ment of type 2 diabetes. A few studies have indicated that acarbose has a modest weight-lowering activity. 35, 36 which may allow the conclusion that the drug is not suitable for weight reduction but should be considered in the treatment of obese type 2 diabetic subjects. Metformin is another established blood glucose lowering agent that reduces hepatic glucose production and increases peripheral insulin sensitivity. A recent meta-analysis of controlled studies on the effect of metformin on body weight revealed that the drug lowers body weight by 1.2 kg 37 in contrast to a weight gain of 1.7 kg after sulfonylurea treatment indicating that metformin may be particularly useful in obese type 2 diabetic patients who have difficulties in controlling weight by diet and exercise. Selective serotonine reuptake inhibitors (SSRI) such as fluoxetine and sertraline are frequently used antidepressant agents. Both were observed to have a weight lowering potential but to lose their weight loss capacity with continued administration. However, for patients who are obese and depressed serotonine reuptake inhibitors may be a more appropriate treatment than other antidepressants such as tricyclic antidepressants which are known to often be associated with weight gain. 4 Topiramate is an antiepileptic drug that acts via GABA receptors. It was observed during clinical studies that long-term use of topiramate induces weight loss. Therefore, this compound is currently being examined for its potential to reduce body weight in obese subjects.
A lot of new data on the regulation of body weight has accumulated in recent years including the discovery of new factors that are involved in this process. 38 Leptin is the product of the obese gene and is mainly expressed by adipocytes. 7 In subsequent studies, leptin was shown to reduce food intake and to increase the activity of the sympathetic nervous system via hypothalamic centers, at least in animal models of obesity. In the first human trial, leptin administration resulted in a dose-dependent reduction in body weight of up to 7.1 kg over 24 weeks but was limited by local skin reactions. 39 Current efforts aim to developing leptin analogues which are more potent and can be taken orally. Another extremely interesting substance is a-MSH, a 13-amino acid peptide produced during the posttranslational processing of proopiomelanocortin (POMC). This peptide was found to reduce food intake in animals, probably by acting as a physiological ligand of the melanocortin-4 (MC-4) receptor. In a recent clinical study, intranasal administration of a-MSH was found to reduce weight in lean humans. 40 
Conclusions
In the past, the pharmacological treatment of obesity was a story of tragedies which caused widespread reservation towards this therapeutical approach. However, the incessant rise in the prevalence of obesity and its complications as well as the development of new and better targeted drugs will certainly lead to a renaissance of drug therapy in the future. There is agreement that new drugs need a thorough examination concerning efficacy and safety issues as drug therapy will change from short-term to long-term use due to the chronic nature of this condition. There is additional necessity to conduct prospective outcome studies to prove that weight-lowering drugs are able to reduce the long-term complications of obesity such as myocardial infarction and stroke. A long-term use of drugs can only be advocated if long-term studies show an overall benefit for treatment in obese subjects. Concerning the future, there is some hope that new developments based on the better understanding of the regulation of food intake and energy expenditure will allow a safer and more effective pharmacological treatment of the obese state.
